Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice

Neonatal brain injury induced by stroke causes significant disability, including cerebral palsy, and there is no effective therapy for stroke. Recently, mesenchymal stem cells (MSCs) have emerged as a promising tool for stem cell-based therapies. In this study, we examined the safety and efficacy of...

Full description

Bibliographic Details
Main Authors: Emi Tanaka, Yuko Ogawa, Takeo Mukai, Yoshiaki Sato, Takashi Hamazaki, Tokiko Nagamura-Inoue, Mariko Harada-Shiba, Haruo Shintaku, Masahiro Tsuji
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Neurology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fneur.2018.00133/full
_version_ 1818252051774177280
author Emi Tanaka
Emi Tanaka
Yuko Ogawa
Takeo Mukai
Yoshiaki Sato
Takashi Hamazaki
Tokiko Nagamura-Inoue
Mariko Harada-Shiba
Haruo Shintaku
Masahiro Tsuji
author_facet Emi Tanaka
Emi Tanaka
Yuko Ogawa
Takeo Mukai
Yoshiaki Sato
Takashi Hamazaki
Tokiko Nagamura-Inoue
Mariko Harada-Shiba
Haruo Shintaku
Masahiro Tsuji
author_sort Emi Tanaka
collection DOAJ
description Neonatal brain injury induced by stroke causes significant disability, including cerebral palsy, and there is no effective therapy for stroke. Recently, mesenchymal stem cells (MSCs) have emerged as a promising tool for stem cell-based therapies. In this study, we examined the safety and efficacy of intravenously administered human umbilical cord-derived MSCs (UC-MSCs) in neonatal stroke mice. Pups underwent permanent middle cerebral artery occlusion at postnatal day 12 (P12), and low-dose (1 × 104) or high-dose (1 × 105) UC-MSCs were administered intravenously 48 h after the insult (P14). To evaluate the effect of the UC-MSC treatment, neurological behavior and cerebral blood flow were measured, and neuroanatomical analysis was performed at P28. To investigate the mechanisms of intravenously injected UC-MSCs, systemic blood flowmetry, in vivo imaging and human brain-derived neurotrophic factor (BDNF) measurements were performed. Functional disability was significantly improved in the high-dose UC-MSC group when compared with the vehicle group, but cerebral blood flow and cerebral hemispheric volume were not restored by UC-MSC therapy. The level of exogenous human BDNF was elevated only in the cerebrospinal fluid of one pup 24 h after UC-MSC injection, and in vivo imaging revealed that most UC-MSCs were trapped in the lungs and disappeared in a week without migration toward the brain or other organs. We found that systemic blood flow was stable over the 10 min after cell administration and that there were no differences in mortality among the groups. Immunohistopathological assessment showed that the percent area of Iba1-positive staining in the peri-infarct cortex was significantly reduced with the high-dose UC-MSC treatment compared with the vehicle treatment. These results suggest that intravenous administration of UC-MSCs is safe for a mouse model of neonatal stroke and improves dysfunction after middle cerebral artery occlusion by modulating the microglial reaction in the peri-infarct cortex.
first_indexed 2024-12-12T16:18:02Z
format Article
id doaj.art-a13c33a5ef0244e7b58623ea9122b2aa
institution Directory Open Access Journal
issn 1664-2295
language English
last_indexed 2024-12-12T16:18:02Z
publishDate 2018-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj.art-a13c33a5ef0244e7b58623ea9122b2aa2022-12-22T00:19:02ZengFrontiers Media S.A.Frontiers in Neurology1664-22952018-03-01910.3389/fneur.2018.00133345800Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke MiceEmi Tanaka0Emi Tanaka1Yuko Ogawa2Takeo Mukai3Yoshiaki Sato4Takashi Hamazaki5Tokiko Nagamura-Inoue6Mariko Harada-Shiba7Haruo Shintaku8Masahiro Tsuji9Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, JapanDepartment of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Cell Processing and Transfusion, Institute of Medical Science, The University of Tokyo, Tokyo, JapanDivision of Neonatology, Center for Maternal-Neonatal Care, Nagoya University Hospital, Nagoya, JapanDepartment of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, JapanDepartment of Cell Processing and Transfusion, Institute of Medical Science, The University of Tokyo, Tokyo, JapanDepartment of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, JapanDepartment of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, JapanDepartment of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center, Suita, JapanNeonatal brain injury induced by stroke causes significant disability, including cerebral palsy, and there is no effective therapy for stroke. Recently, mesenchymal stem cells (MSCs) have emerged as a promising tool for stem cell-based therapies. In this study, we examined the safety and efficacy of intravenously administered human umbilical cord-derived MSCs (UC-MSCs) in neonatal stroke mice. Pups underwent permanent middle cerebral artery occlusion at postnatal day 12 (P12), and low-dose (1 × 104) or high-dose (1 × 105) UC-MSCs were administered intravenously 48 h after the insult (P14). To evaluate the effect of the UC-MSC treatment, neurological behavior and cerebral blood flow were measured, and neuroanatomical analysis was performed at P28. To investigate the mechanisms of intravenously injected UC-MSCs, systemic blood flowmetry, in vivo imaging and human brain-derived neurotrophic factor (BDNF) measurements were performed. Functional disability was significantly improved in the high-dose UC-MSC group when compared with the vehicle group, but cerebral blood flow and cerebral hemispheric volume were not restored by UC-MSC therapy. The level of exogenous human BDNF was elevated only in the cerebrospinal fluid of one pup 24 h after UC-MSC injection, and in vivo imaging revealed that most UC-MSCs were trapped in the lungs and disappeared in a week without migration toward the brain or other organs. We found that systemic blood flow was stable over the 10 min after cell administration and that there were no differences in mortality among the groups. Immunohistopathological assessment showed that the percent area of Iba1-positive staining in the peri-infarct cortex was significantly reduced with the high-dose UC-MSC treatment compared with the vehicle treatment. These results suggest that intravenous administration of UC-MSCs is safe for a mouse model of neonatal stroke and improves dysfunction after middle cerebral artery occlusion by modulating the microglial reaction in the peri-infarct cortex.http://journal.frontiersin.org/article/10.3389/fneur.2018.00133/fullmesenchymal stem cellumbilical cord-derived mesenchymal stem cellneonatal strokeneonatal brain injuryintravenous administration
spellingShingle Emi Tanaka
Emi Tanaka
Yuko Ogawa
Takeo Mukai
Yoshiaki Sato
Takashi Hamazaki
Tokiko Nagamura-Inoue
Mariko Harada-Shiba
Haruo Shintaku
Masahiro Tsuji
Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice
Frontiers in Neurology
mesenchymal stem cell
umbilical cord-derived mesenchymal stem cell
neonatal stroke
neonatal brain injury
intravenous administration
title Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice
title_full Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice
title_fullStr Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice
title_full_unstemmed Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice
title_short Dose-Dependent Effect of Intravenous Administration of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Stroke Mice
title_sort dose dependent effect of intravenous administration of human umbilical cord derived mesenchymal stem cells in neonatal stroke mice
topic mesenchymal stem cell
umbilical cord-derived mesenchymal stem cell
neonatal stroke
neonatal brain injury
intravenous administration
url http://journal.frontiersin.org/article/10.3389/fneur.2018.00133/full
work_keys_str_mv AT emitanaka dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT emitanaka dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT yukoogawa dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT takeomukai dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT yoshiakisato dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT takashihamazaki dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT tokikonagamurainoue dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT marikoharadashiba dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT haruoshintaku dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice
AT masahirotsuji dosedependenteffectofintravenousadministrationofhumanumbilicalcordderivedmesenchymalstemcellsinneonatalstrokemice